Company Overview and News

100
Stop Buying Commodities Funds

2018-06-19 seekingalpha
We’ve never been fans of direct commodities investments and have been warning about the lack of risk adjusted returns that commodities funds offer investors for years. In previous articles, we focused on the structural issues with commodities markets and commodities funds that make them unworthy of inclusion in investors’ portfolios. In this article, we want to focus on a different aspect of commodities funds that make them unattractive.
HAL RIO RIO BLT XOM APD PSX COP SHW RTPPF RTNTF VDE BHPBF VLO DWDP VALE PPG PX BHP RIO CVX DBC VAW BBL BHP PDBC SLB BHPLF AI

1
Let Sherwin Williams Paint Your Portfolio Green

2018-06-06 seekingalpha
What’s even less fun than watching paint dry? Thinking about paint stocks. They simply can’t hold a candle to the excitement induced by the company ushering in the next era of smartphones, or the organization that squeezes more functionality out of the cloud.
SHW

332
The 10 Best Stocks to Buy for the Next Decade

2018-06-01 investorplace
Last year, InvestorPlace contributor Dan Burrows highlighted the 10 best-performing S&P 500 stocks of the past decade. The most important lesson one finds studying these high-flying stocks is that patience wins out over all other attributes of a successful investor.
BUFF FMAGX UL ULTA RSMDF THI BRK.A SHW RMD VAL AMZN PPG KHC AAPL RMD CBRL FIVE DIS

3
SHW / Sherwin-Williams Co. (The) SD

2018-05-30 sec.gov
SD UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
SHW

32
Is PowerShares DWA Industrials Momentum Portfolio (PRN) a Hot ETF Right Now?

2018-05-30 zacks
The PowerShares DWA Industrials Momentum Portfolio (PRN - Free Report) made its debut on 10/12/2006, and is a smart beta exchange traded fund that provides broad exposure to the Industrials ETFs category of the U.S. equity market.
SHW AME VIS

1000
Tracking Dan Loeb's Third Point Portfolio - Q1 2018 Update

2018-05-22 seekingalpha
Dan Loeb's 13F portfolio value decreased from $13.86B to $13.32B this quarter. The number of positions decreased from 44 to 40.
PCG ATHTF STZ.B TWX CVS CRM SHW GGAL HON AABA AVGO DOW DOV MELI MAC AET MMM PBF GD TPRE WP KDMN UTX STZ BKI TWC BABA DVMT GOOGL MSFT APY MHK QCOM GRBK MGM FB DOV.WI LEN NXPI PAM PE NFLX PF GOOG BAX LEN.B MPC PAGS ADBE SPGI RSPP VMC MON ICE SWN HON EA WYNN LYB FTI.WI FMC ANTM DWDP BID NEXA BLK XRAY T SUPV DHR ANTX

1
Ask Sherwin Williams

2018-05-18 seekingalpha
Over the last 10 years SHW has increased the dividend at a CAGR of more than 10%.
SHW

44
7 Fast-Growing Stocks to Buy Today

2018-05-08 investorplace
Editor’s Note: This is a replay of a story that originally ran March 2, 2018. It has since been updated and republished.
LOW VRTX RDS.B RDS.A XOM KNX RDSB VLO RDSA SHW KRO RYDBF LITE RYDAF

2
SHW / Sherwin-Williams Co. (The) 10-Q (Quarterly Report)

2018-04-25 sec.gov
Document UNITED STATES
SHW

3
SHW / Sherwin-Williams Co. (The) FORM 8-K (Current Report)

2018-04-24 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SHW

2
SHW / Sherwin-Williams Co. (The) FORM 8-K (Current Report)

2018-04-23 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
SHW

1
What Will It Take for Sherwin-Williams to Beat Analyst Estimates?

2018-04-20 marketrealist
Sherwin Williams (SHW) is expected to post adjusted EPS (earnings per share) of $3.17 in 1Q18, an increase of ~39.7% YoY (year-over-year). In 1Q17, SHW reported adjusted EPS of $2.27.
SHW VAW

332
The 10 Best Stocks to Buy for the Next Decade

2018-04-16 investorplace
Last year, InvestorPlace contributor Dan Burrows highlighted the 10 best-performing S&P 500 stocks of the past decade. The most important lesson one finds studying these high-flying stocks is that patience wins out over all other attributes of a successful investor.
BUFF FMAGX UL ULTA RSMDF THI BRK.A SHW RMD VAL AMZN PPG KHC AAPL RMD CBRL FIVE DIS

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

2018-06-22 - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

2018-06-22 - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

Silicon Investor Message Boards

This table lists all message boards related to SHW / Sherwin-Williams Co. (The) on message board site Silicon Investor.

ASHWORTH INC (Nasdaq: ASHW) ASHW: Ashworth, Inc.
PolishWorld.com.on.in Shearhart Corporation (SHW) Home and Rural
All clowns must be destroyed, gr. links II - the crashwave SHWK - Seahawk Deep Ocean Tech, Inc.
PCSH - Payless Cashways SHWC
Payless Cashways- In Chapter 11 (PYLSQ-OTCBB)
CUSIP: 824348106